AU Patent

AU2021245150A1 — KRAS G12C inhibitors and methods of using the same

Assigned to Amgen Inc · Expires 2021-11-04 · 5y expired

What this patent protects

KRAS G12C INHIBITORS AND METHODS OF USING THE SAME Abstract Provided herein are KRAS G 1 2C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.

USPTO Abstract

KRAS G12C INHIBITORS AND METHODS OF USING THE SAME Abstract Provided herein are KRAS G 1 2C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.

Drugs covered by this patent

Patent Metadata

Patent number
AU2021245150A1
Jurisdiction
AU
Classification
—
Expires
2021-11-04
Drug substance claim
No
Drug product claim
No
Assignee
Amgen Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.